Clinical Trial

Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

Terminated Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Portfolio prioritization
Summary
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of ALPP CAR-T cells in patients with ALPP-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-31.
Status change: Recruiting → Terminated 2026-01-19
Trial Details
NCT Number NCT07108140
Lead Sponsor TCRCure Biopharma Ltd.
Collaborators: Nanjing University School of Medicine
Conditions Solid Tumor
Enrollment 5 participants
Start Date 2025-05-20
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-01-16 (estimated)
Updated on ClinicalTrials.gov 2026-01-22